The verdict
Our read at a glance.
Whether ARA-290's tissue-protective mechanism produces real benefit in the specific nerve conditions it is studied for, separate from broad repair or anti-inflammatory claims.
- The signal
- Small early trials have tested ARA-290 in small-fiber neuropathy linked to sarcoidosis and in diabetic neuropathy, with mixed and preliminary results. The evidence base is limited and there is no approval for any use.
- The unknown
- Whether its early signals in neuropathy hold up in larger trials, and whether any tissue-protective effect is meaningful outside the specific conditions studied, which has not been shown.
- Our read
- An early, targeted investigational peptide for nerve conditions, not a proven repair therapy. ARA-290's tissue-protective idea is biologically plausible, but the human evidence is small and mixed, so it should be read as investigational and limited to the conditions it is studied in.
The mechanism
How it works.
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide copied from the tissue-protective part of erythropoietin, but engineered so it does not raise red blood cells. It binds the innate repair receptor, a complex of the erythropoietin receptor and the beta-common receptor (CD131), which dampens inflammatory signaling and is proposed to support nerve and small-blood-vessel repair. That receptor-level idea is the rationale for testing it in neuropathy, but the effect rests on animal and early human data and has not been confirmed in large human trials.
Safety & regulatory boundary
The consequential part.
ARA-290 is investigational and not an approved product. Its evidence is early and limited, and results in one condition do not transfer to others. Research-labeled or compounded ARA-290 is not an approved product, and its development status does not support use outside trials. Its mechanism does not validate broad repair, recovery, or anti-aging claims.
What's next
What we're watching.
Larger controlled trials in neuropathy, any regulatory progress, and longer-term safety data.
Context
Why this is discussed.
ARA-290 is of interest because it aims to capture the tissue-protective effects associated with erythropoietin without raising red blood cells, with most attention on hard-to-treat nerve pain.
The evidence base
16 cited references.
Registered trials4
ClinicalTrials.gov · PHASE2 · TERMINATED · 2016-04
ClinicalTrials.gov · PHASE2 · COMPLETED · 2014-01
ClinicalTrials.gov · PHASE2 · UNKNOWN · 2013-10
ClinicalTrials.gov · PHASE1/PHASE2 · COMPLETED · 2012-02
Indexed literature (PubMed)12
Tracey KJ · Mol Med · 2013
van Velzen M et al. · Expert Opin Investig Drugs · 2014
Zhang W et al. · Peptides · 2016
Rendell MS · Expert Opin Investig Drugs · 2021
Al-Onaizi MA et al. · Brain Behav Immun · 2022
Nairz M et al. · Sci Rep · 2017
Watanabe M et al. · Transplantation · 2016
Brines M et al. · Mol Med · 2015
Yao M et al. · Cell Transplant · 2021
Yao M et al. · Transplantation · 2020
Mohtavinejad N et al. · Iran J Basic Med Sci · 2021
Lois N et al. · J Clin Med · 2020
Keep reading